ALXN News and Press, Alexion Pharmaceuticals Inc. From 07/26/20

Many investors have made tons of money by investing in small-cap biotech stocks, especially those that are still relatively obscure. One potential investment candidate that's slipped under the radar due to the coronavirus pandemic is Omeros Corporation (NASDAQ: OMER) . A biotech company that ...

An uptick in U.S. jobless claims this week is a reminder there's still a real risk of permanent job loss that could spike credit defaults and weigh down economic activity. The expiration of the $600 weekly unemployment bonus and the potential for large employers to use COVID-19 uncertain...

This article series has been releasing every month since 2015 a dashboard with aggregate industry metrics in healthcare (most popular ETFs in this sector: XLV , IYH , IBB , XBI , VHT , XPH ). Shortcut If you are used to this dashboard series or if you are short of time, you can s...

Quick Take Annexon ( ANNX ) intends to raise $150 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is developing treatments for autoimmune and neurodegenerative conditions. ANNX is pursuing multiple treatment programs with...

Source : ClearBridge Investments Editor's Note : The summary bullets for this article were chosen by Read more ...

Inozyme Pharma ( INZY )  acquires intellectual property and assets focusing on ENPP1 gene deficiencies, from Alexion Pharmaceuticals (NASDAQ: ALXN ) . More news on: Inozyme Pharma, Inc., Alexion Pharmaceuticals, Inc., Healthcare stocks news, Merger & acquisition news, Read m...

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the second quarter ended June 30, 2020 before the US financial markets open on July 30, 2020. Following the release of the financial results, Alexion management will conduct a c...

The second half of the year could provide some solid wins for investors in the cancer therapeutics market. In recent years, Wall Street has flocked to many of these biotechnology companies because of their potential to deliver cutting-edge treatments and generate long-term returns. As cancer ...

Revenue clarity and accelerating growth in the middle of recession suggests top stocks deserve premium valuations, but stocks don't rise or fall in a straight line, so expecting some form of mean reversion is understandable. That said, stocks tend to climb higher and fall further than most...

Longtime investors have seen some crazy things transpire over the years, but nothing could have prepared them for the volatility caused by the coronavirus disease 2019 (COVID-19) pandemic. With the first-half of 2020 now in the books, we've witnessed the benchmark S&P 500 lose more than a ...